Esperion Therapeutics Inc - Understand $espr stock

$ESPR Market Cap: $439.4 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$295.5M

TTM

Gross Margin

75.64%

TTM

Net Earnings

-$86.77M

TTM

Current Assets

$307.6M

Q3 2024

Current Liabilities

$165.9M

Q3 2024

Current Ratio

185.42%

Q3 2024

Total Assets

$314.1M

Q3 2024

Total Liabilities

$684.3M

Q3 2024

Book Value

-$370.2M

Q3 2024

Cash

$144.7M

Q3 2024

P/E

-5.064

Nov 13, 2024 EST

Free Cash Flow

$10.98M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Revenue	$116.3M	$75.48M	$78.45M	$227.5M	$148.4M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	54.14%	-3.79%	-65.52%	53.37%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Revenue	$116.3M	$75.48M	$78.45M	$227.5M	$148.4M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$43.27M	$26.97M	$14.22M	$2.400M
Gross Profit	$73.07M	$48.51M	$64.23M	$225.2M
Gross Profit Margin	62.81%	64.27%	81.88%	98.97%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Selling, General & Admin	$142.5M	$109.1M	$185.0M	$199.6M	$65.85M	$33.10M	$21.40M	$18.30M	$20.20M	$10.90M	$6.700M	$2.200M	$2.400M	$5.400M	$5.000M	$4.000M	$2.500M	$500.0K
YoY Change	30.66%	-41.03%	-7.33%	203.12%	98.97%	54.66%	16.94%	-9.41%	85.32%	62.69%	204.55%	-8.33%		8.0%	25.0%	60.0%	400.0%
% of Gross Profit	195.06%	224.87%	288.0%	88.64%
Research & Development	$86.11M	$118.9M	$106.0M	$146.9M	$175.6M	$171.5M	$147.6M	$57.90M	$29.80M	$25.30M	$16.01M	$7.998M	$7.808M	$22.00M	$21.50M	$21.80M	$8.500M	$1.900M
YoY Change	-27.6%	12.22%	-27.88%	-16.33%	2.4%	16.18%	154.93%	94.3%	17.79%	57.98%	100.22%	2.44%		2.33%	-1.38%	156.47%	347.37%
% of Gross Profit	117.85%	245.17%	164.99%	65.25%
Depreciation & Amortization	$200.0K	$500.0K	$600.0K	$500.0K	$300.0K	$300.0K	$300.0K	$250.0K	$240.0K	$160.0K	$70.55K	$139.4K	$178.5K	$1.290M	$2.010M	$1.040M	$400.0K	$70.00K
YoY Change	-60.0%	-16.67%	20.0%	66.67%	0.0%	0.0%	20.0%	4.17%	50.0%	126.79%	-49.4%	-21.87%		-35.82%	93.27%	160.0%	471.43%
% of Gross Profit	0.27%	1.03%	0.93%	0.22%
Operating Expenses	$271.9M	$255.0M	$305.2M	$348.9M	$241.5M	$204.6M	$169.0M	$76.20M	$50.00M	$36.20M	$22.76M	$10.20M	$7.808M	$27.30M	$27.30M	$26.00M	$11.00M	$2.400M
YoY Change	6.64%	-16.45%	-12.54%	44.51%	18.03%	21.07%	121.76%	52.4%	38.12%	59.06%	123.04%	30.69%		0.0%	5.0%	136.36%	358.33%
Operating Profit	-$155.6M	-$179.5M	-$226.7M	-$121.4M	-$93.10M	-$204.6M	-$169.0M				-$22.76M	-$10.20M	-$10.16M
YoY Change	-13.34%	-20.83%	86.77%	30.39%	-54.49%	21.07%					123.04%	0.39%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Interest Expense	$58.98M	$56.81M	$46.35M	$22.67M	$8.120M	$28.00K	$198.0K	-$400.0K	-$500.0K	-$300.0K	$936.6K	$1.487M	$577.2K	$0.00	$2.100M	$2.200M	$300.0K	$200.0K
YoY Change	3.81%	22.56%	104.47%	179.19%	28900.0%	-85.86%	-149.5%	-20.0%	66.67%	-132.03%	-37.0%	157.59%		-100.0%	-4.55%	633.33%	50.0%
% of Operating Profit
Other Income/Expense, Net	$5.291M	$2.652M	$3.975M	$515.0K	$4.056M	$2.803M	$2.192M	$1.500M	$800.0K	$100.0K	$194.0K	-$100.0K	-$75.81K	-$700.0K	$300.0K	$200.0K	$0.00	$0.00
YoY Change	99.51%	-33.28%	671.84%	-87.3%	44.7%	27.87%	46.13%	87.5%	700.0%	-48.46%	-294.01%	31.9%		-333.33%	50.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Pretax Income	-$209.2M	-$233.7M	-$269.1M	-$143.6M	-$97.20M	-$201.8M	-$167.0M	-$75.00M	-$49.80M	-$36.40M	-$26.10M	-$11.70M	-$10.80M	-$28.70M	-$24.90M	-$27.60M	-$10.70M	-$2.100M
YoY Change	-10.45%	-13.17%	87.4%	47.74%	-51.83%	20.84%	122.67%	50.6%	36.81%	39.46%	123.08%	8.33%		15.26%	-9.78%	157.94%	409.52%
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$209.2M	-$233.7M	-$269.1M	-$143.6M	-$97.17M	-$201.8M	-$167.0M	-$75.00M	-$49.80M	-$36.40M	-$26.10M	-$11.74M	-$10.82M	-$28.70M	-$24.90M	-$27.60M	-$10.70M	-$2.100M
YoY Change	-10.45%	-13.17%	87.47%	47.74%	-51.85%	20.85%	122.65%	50.6%	36.81%	39.46%	122.28%	8.55%		15.26%	-9.78%	157.94%	409.52%
Net Earnings / Revenue	-179.87%	-309.58%	-343.04%	-63.09%	-65.49%
Basic Earnings Per Share	-$2.03	-$3.52	-$9.31	-$5.23	-$3.59
Diluted Earnings Per Share	-$2.03	-$3.52	-$9.31	-$5.23	-$3.59	-$7.530M	-$6.987M	-$3.333M	-$2.264M	-$2.220M	-$3.304M	-$39.00M	-$36.00M	-$979.5K	-$912.1K	-$1.070M	-$5.944M	-$1.400M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2002	2001	2000	1999	1998
Cash & Short-Term Investments	$82.25M	$166.9M	$259.3M	$305.0M	$200.8M	$136.0M	$200.2M	$211.6M	$212.3M	$105.8M	$60.10M	$6.500M	$1.600M	$44.90M	$70.30M	$70.20M	$5.900M	$12.50M
YoY Change	-50.71%	-35.66%	-14.97%	51.89%	47.65%	-32.07%	-5.39%	-0.33%	100.66%	76.04%	824.62%	306.25%		-36.13%	0.14%	1089.83%	-52.8%
Cash & Equivalents	$82.25M	$124.8M	$208.9M	$305.0M	$166.1M	$37.00M	$34.50M	$38.20M	$77.30M	$85.00M	$56.50M	$6.500M	$1.600M	$40.50M	$70.30M	$70.20M	$5.900M	$12.50M
Short-Term Investments	$0.00	$42.09M	$50.44M	$0.00	$34.70M	$99.10M	$165.7M	$173.4M	$134.9M	$20.80M	$3.500M			$4.400M
Other Short-Term Assets	$4.700M	$10.89M	$12.31M	$24.80M	$10.90M	$6.600M	$3.700M	$2.000M	$2.100M	$900.0K	$600.0K	$600.0K	$300.0K	$400.0K	$1.000M	$1.100M	$100.0K	$100.0K
YoY Change	-56.85%	-11.53%	-50.36%	127.52%	65.15%	78.38%	85.0%	-4.76%	133.33%	50.0%	0.0%	100.0%		-60.0%	-9.09%	1000.0%	0.0%
Inventory	$65.62M	$35.20M	$34.39M	$16.10M
Prepaid Expenses
Receivables	$48.49M	$33.73M	$22.93M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$201.1M	$246.7M	$329.0M	$345.9M	$211.7M	$142.6M	$203.9M	$213.6M	$214.4M	$106.7M	$60.60M	$7.100M	$1.900M	$45.30M	$71.30M	$71.30M	$6.000M	$12.60M
YoY Change	-18.49%	-25.01%	-4.89%	63.39%	48.46%	-30.06%	-4.54%	-0.37%	100.94%	76.07%	753.52%	273.68%		-36.47%	0.0%	1088.33%	-52.38%
Property, Plant & Equipment	$4.675M	$1.200M	$2.562M	$7.300M	$2.700M	$500.0K	$400.0K	$700.0K	$800.0K	$800.0K	$100.0K	$100.0K	$300.0K	$3.000M	$3.300M	$2.500M	$2.000M	$800.0K
YoY Change	289.58%	-53.16%	-64.9%	170.37%	440.0%	25.0%	-42.86%	-12.5%	0.0%	700.0%	0.0%	-66.67%		-9.09%	32.0%	25.0%	150.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments						$200.0K	$73.40M	$30.90M	$80.30M	$35.70M	$17.50M
YoY Change						-99.73%	137.54%	-61.52%	124.93%	104.0%
Other Assets		$0.00	$50.00M										$0.00	$0.00	$600.0K	$500.0K	$0.00
YoY Change		-100.0%												-100.0%	20.0%
Total Long-Term Assets	$4.731M	$1.256M	$52.62M	$7.400M	$2.700M	$900.0K	$73.90M	$31.60M	$81.20M	$36.60M	$17.70M	$200.0K	$300.0K	$6.100M	$7.000M	$6.600M	$2.000M	$800.0K
YoY Change	276.67%	-97.61%	611.05%	174.07%	200.0%	-98.78%	133.86%	-61.08%	121.86%	106.78%	8750.0%	-33.33%		-12.86%	6.06%	230.0%	150.0%
Total Assets	$205.8M	$247.9M	$381.6M	$353.3M	$214.4M	$143.5M	$277.8M	$245.2M	$295.6M	$143.3M	$78.30M	$7.300M	$2.200M	$51.40M	$78.30M	$77.90M	$8.000M	$13.40M
YoY Change
Accounts Payable	$31.72M	$23.04M	$17.56M	$52.00M	$28.90M	$44.90M	$20.40M	$4.600M	$700.0K	$2.000M	$2.200M	$500.0K	$700.0K	$1.700M	$2.900M	$3.900M	$1.400M	$100.0K
YoY Change	37.66%	31.21%	-66.23%	79.93%	-35.63%	120.1%	343.48%	557.14%	-65.0%	-9.09%	340.0%	-28.57%		-41.38%	-25.64%	178.57%	1300.0%
Accrued Expenses	$64.28M	$41.00M	$38.82M	$35.00M	$29.80M	$19.40M	$11.70M	$9.300M	$3.300M	$2.800M	$2.000M	$1.200M	$600.0K	$2.200M	$2.600M	$2.500M	$1.000M	$100.0K
YoY Change	56.77%	5.63%	10.9%	17.45%	53.61%	65.81%	25.81%	181.82%	17.86%	40.0%	66.67%	100.0%		-15.38%	4.0%	150.0%	900.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$15.20M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change											-100.0%
Long-Term Debt Due						$0.00	$1.000M	$1.700M	$1.600M	$600.0K				$1.100M	$900.0K	$700.0K	$500.0K	$0.00
YoY Change						-100.0%	-41.18%	6.25%	166.67%					22.22%	28.57%	40.0%
Total Short-Term Liabilities	$156.2M	$92.31M	$73.35M	$94.10M	$66.10M	$64.30M	$33.10M	$15.60M	$5.600M	$5.500M	$4.200M	$17.20M	$1.300M	$4.900M	$6.400M	$7.200M	$2.900M	$200.0K
YoY Change	69.24%	25.84%	-22.05%	42.36%	2.8%	94.26%	112.18%	178.57%	1.82%	30.95%	-75.58%	1223.08%		-23.44%	-11.11%	148.28%	1350.0%
Long-Term Debt	$261.6M	$259.9M	$258.3M	$179.4M	$0.00	$0.00	$0.00	$1.000M	$2.700M	$4.200M	$0.00	$7.500M	$6.900M	$7.700M	$5.500M	$3.000M	$2.300M	$0.00
YoY Change	0.65%	0.63%	43.97%				-100.0%	-62.96%	-35.71%		-100.0%	8.7%		40.0%	83.33%	30.43%
Other Long-Term Liabilities	$243.0M	$219.5M	$246.9M	$176.0M	$128.4M
YoY Change	10.69%	-11.09%	40.29%	37.07%
Total Long-Term Liabilities	$504.6M	$479.4M	$505.2M	$355.4M	$128.4M	$0.00	$0.00	$1.000M	$2.700M	$4.200M	$0.00	$7.500M	$6.900M	$7.700M	$5.500M	$3.000M	$2.300M	$0.00
YoY Change	5.25%	-5.1%	42.14%	176.79%			-100.0%	-62.96%	-35.71%		-100.0%	8.7%		40.0%	83.33%	30.43%
Total Liabilities	$660.8M	$571.7M	$578.5M	$449.4M	$194.5M	$64.30M	$33.10M	$16.60M	$8.300M	$9.700M	$4.200M	$24.70M	$8.200M	$12.70M	$11.80M	$10.20M	$5.200M	$200.0K
YoY Change	15.58%	-1.18%	28.73%	131.05%	202.49%	94.26%	99.4%	100.0%	-14.43%	130.95%	-83.0%	201.22%		7.63%	15.69%	96.15%	2500.0%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	103.1M shares	66.41M shares	28.90M shares	27.47M shares	27.09M shares
Diluted Shares Outstanding	103.1M shares	66.41M shares	28.90M shares	27.47M shares	27.09M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $439.39 Million

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Vero Beach, Florida and currently employs 240 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The firm's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The firm's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Industry: Pharmaceutical Preparations Peers: Atea Pharmaceuticals Inc Cara Therapeutics Inc Edgewise Therapeutics Inc Evolus Inc Fulcrum Therapeutics Inc Ocular Therapeutix Inc Johnson & Johnson Nuvation Bio Inc Rani Therapeutics Holdings, Inc. Tarsus Pharmaceuticals Inc